牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals Inc officer, DAVID S JONES, is set to sell 34,442 shares of common stock on 01/24/2024, as per the latest SEC filings. The shares, valued at approximately $857,950.22, were acquired on the same day through the exercise of stock options, with payment made in cash to the issuer. This transaction follows a recent history of sales by JONES over the past three months, totaling 35,066 shares for gross proceeds of $795,191.34.
EyePoint Pharmaceuticals Inc officer, DAVID S JONES, is set to sell 34,442 shares of common stock on 01/24/2024, as per the latest SEC filings. The shares, valued at approximately $857,950.22, were acquired on the same day through the exercise of stock options, with payment made in cash to the issuer. This transaction follows a recent history of sales by JONES over the past three months, totaling 35,066 shares for gross proceeds of $795,191.34.
根據美國證券交易委員會的最新文件，EyePoint Pharmicals Inc高管戴維·瓊斯定於2024年1月24日出售34,442股普通股。這些股票價值約857,950.22美元，於當天通過行使股票期權收購，並以現金支付給發行人。該交易遵循了瓊斯在過去三個月中的近期銷售記錄，共計35,066股股票，總收益爲795,191.34美元。
根據美國證券交易委員會的最新文件，EyePoint Pharmicals Inc高管戴維·瓊斯定於2024年1月24日出售34,442股普通股。這些股票價值約857,950.22美元，於當天通過行使股票期權收購，並以現金支付給發行人。該交易遵循了瓊斯在過去三個月中的近期銷售記錄，共計35,066股股票，總收益爲795,191.34美元。
有用
沒用
該公告為獨立文件：